Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alexion
Pharma
AZ loses $130M to Syntimmune shareholders in post-merger suit
A Delaware judge agreed that AZ's Alexion failed to pay $130 million in milestone tied to the development of a now scrapped Syntimmune drug.
Zoey Becker
Sep 9, 2024 11:43am
Amgen grabs FDA thumbs-up for Soliris biosim, eyes 2025 launch
May 29, 2024 10:26am
AZ's Alexion debuts short film highlighting NMOSD community
Apr 18, 2024 2:16pm
FDA expands AZ's Ultomiris to NMOSD after prior rejection
Mar 25, 2024 10:31am
AZ's newest PNH med Voydeya approved in Japan
Jan 19, 2024 11:06am
Alexion inks $125M deal to resolve investor lawsuit
Sep 14, 2023 11:41am
